Hospital
Summerlin Hospital Medical Center L L C
Summerlin Hospital Medical Center L L C was paid $30.26M by Medicaid between Jan 2018 and Dec 2024, across 291 billing codes. Its largest line is 99285, emergency room visit (most serious) — 17% of everything it billed.
33Billing provider infoSUMMERLIN HOSPITAL MEDICAL CENTER L L C
LAS VEGAS, NV 89144
LAS VEGAS, NV 89144
33aNPI1831189638assigned 10/24/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$30.26M
24GClaims1,395,340
24DCodes billed291
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Nevada
Rank by total paid#8 of 36
Median peer was paid$7.64M
This provider vs. median4.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official FILTON, STEVE controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 91,324 | $1.25M | |
| 2019 | 244,331 | $4.90M | |
| 2020 | 206,427 | $4.15M | |
| 2021 | 223,780 | $5.02M | |
| 2022 | 215,585 | $5.05M | |
| 2023 | 229,782 | $5.39M | |
| 2024incomplete | 184,111 | $4.49M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 17% | 45,863 | 38,249 | $5.18M |
| G0378 | Hospital observation service, per hour | 8.3% | 21,566 | 15,530 | $2.51M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 7.9% | 26,491 | 24,003 | $2.39M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 7.0% | 9,194 | 7,832 | $2.13M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 6.2% | 34,651 | 30,085 | $1.87M |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 2.8% | 32,024 | 7,083 | $859K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.7% | 9,156 | 7,897 | $803K |
| 54161 | 2.6% | 2,140 | 2,025 | $794K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | 2.4% | 2,971 | 2,534 | $715K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 2.1% | 3,944 | 3,329 | $647K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.8% | 33,892 | 26,445 | $536K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.6% | 23,278 | 4,444 | $489K |
279 more codes
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.6% | 2,368 | $481K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.6% | 28,354 | $479K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 1.5% | 14,360 | $458K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.5% | 25,024 | $448K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.2% | 9,892 | $356K |
| 59025 | Fetal non-stress test | 1.1% | 10,115 | $342K |
| 54300 | 1.1% | 401 | $331K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 13,481 | $297K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 9,079 | $287K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 582 | $225K |
| 80053 | Comprehensive metabolic panel | <1% | 48,971 | $221K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 70,447 | $212K |
| 96376 | <1% | 14,944 | $210K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 15,430 | $209K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 6,946 | $198K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,771 | $191K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 14,601 | $188K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 967 | $182K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 2,186 | $181K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 2,831 | $170K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 13,513 | $169K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 3,071 | $157K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 34,022 | $151K |
| 14040 | <1% | 821 | $148K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 2,023 | $136K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 2,564 | $131K |
| P9040 | Red blood cells, leukocytes reduced, irradiated, each unit | <1% | 1,681 | $129K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 582 | $126K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 3,567 | $123K |
| 71045 | Radiologic examination, chest; single view | <1% | 20,496 | $123K |
| 36415 | Collection of venous blood by venipuncture | <1% | 89,447 | $120K |
| 76830 | Ultrasound, transvaginal | <1% | 1,710 | $119K |
| 76801 | <1% | 2,023 | $118K | |
| 84484 | <1% | 28,256 | $117K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 1,219 | $108K |
| 84702 | <1% | 18,706 | $105K | |
| 0450 | Emergency room services | <1% | 2,035 | $101K |
| 97161 | <1% | 3,846 | $97K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 1,117 | $92K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 539 | $89K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 6,156 | $87K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 2,379 | $87K |
| 70496 | <1% | 254 | $84K | |
| 72131 | <1% | 612 | $81K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 26,677 | $78K |
| 36430 | <1% | 3,343 | $72K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 6,207 | $70K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,346 | $68K |
| 93971 | <1% | 1,397 | $66K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 2,457 | $65K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 1,749 | $64K |
| 70498 | <1% | 286 | $64K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 3,513 | $64K |
| 97165 | <1% | 2,565 | $62K | |
| 54360 | <1% | 106 | $59K | |
| 93970 | <1% | 741 | $59K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 2,396 | $56K |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 490 | $56K |
| 83880 | <1% | 4,975 | $54K | |
| 83690 | <1% | 18,675 | $53K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 4,449 | $52K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 21,185 | $47K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 4,432 | $47K |
| 74018 | <1% | 3,864 | $46K | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 615 | $45K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 743 | $42K |
| 87040 | <1% | 8,694 | $42K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 12,494 | $41K |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 482 | $40K |
| 86902 | <1% | 1,067 | $40K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,964 | $40K |
| 83605 | <1% | 9,493 | $38K | |
| 94644 | <1% | 1,245 | $35K | |
| 92526 | <1% | 803 | $33K | |
| 81001 | <1% | 24,763 | $33K | |
| 54304 | <1% | 38 | $33K | |
| 85730 | <1% | 17,781 | $32K | |
| 73564 | <1% | 1,423 | $29K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 31,634 | $26K |
| 83735 | <1% | 12,085 | $25K | |
| 81025 | <1% | 11,908 | $25K | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 1,827 | $25K |
| 85610 | <1% | 21,761 | $25K | |
| 85379 | <1% | 5,320 | $22K | |
| 87641 | <1% | 3,881 | $22K | |
| 73630 | <1% | 1,336 | $22K | |
| 90715 | <1% | 420 | $22K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 363 | $21K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 5,908 | $21K |
| 73610 | <1% | 1,137 | $21K | |
| 84112 | <1% | 1,538 | $20K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 9,939 | $20K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 255 | $19K |
| 97602 | <1% | 1,080 | $18K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 1,393 | $18K |
| 58662 | <1% | 13 | $18K | |
| 84145 | <1% | 1,563 | $17K | |
| 87186 | <1% | 4,753 | $16K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,361 | $16K |
| 86923 | <1% | 2,912 | $16K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 10,840 | $15K |
| 70486 | <1% | 138 | $15K | |
| 73130 | <1% | 850 | $15K | |
| 86140 | <1% | 6,570 | $15K | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 1,790 | $14K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 837 | $13K |
| 80076 | <1% | 4,020 | $13K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 821 | $13K |
| 70491 | <1% | 73 | $13K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 15,324 | $12K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 10,863 | $12K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,552 | $12K |
| 94664 | <1% | 1,382 | $12K | |
| 76775 | <1% | 433 | $12K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 3,250 | $12K |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 1,902 | $11K |
| 73030 | <1% | 838 | $11K | |
| 85027 | <1% | 9,777 | $11K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 217 | $11K |
| 87507 | <1% | 272 | $11K | |
| 81003 | <1% | 12,429 | $10K | |
| 82962 | <1% | 15,196 | $10K | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 1,496 | $10K |
| 86850 | <1% | 8,693 | $10K | |
| 93017 | <1% | 582 | $10K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 253 | $9K |
| 82731 | <1% | 430 | $9K | |
| 82803 | <1% | 1,483 | $9K | |
| 80061 | Lipid panel | <1% | 2,417 | $9K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 61 | $9K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 900 | $9K |
| 82550 | <1% | 3,512 | $9K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 3,382 | $9K |
| J2704 | Injection, propofol, 10 mg | <1% | 13,842 | $9K |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 53 | $8K |
| 86901 | <1% | 10,052 | $8K | |
| 86900 | <1% | 9,734 | $8K | |
| 73110 | <1% | 398 | $8K | |
| 87077 | <1% | 1,934 | $8K | |
| 87631 | <1% | 2,440 | $8K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 5,378 | $8K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,660 | $7K |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 1,835 | $7K |
| 81002 | <1% | 5,656 | $7K | |
| C1769 | Guide wire | <1% | 2,161 | $6K |
| 82805 | <1% | 476 | $6K | |
| 12011 | <1% | 118 | $5K | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 1,282 | $5K |
| 72100 | <1% | 377 | $5K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 8,509 | $5K |
| 73090 | <1% | 336 | $5K | |
| 80074 | <1% | 482 | $5K | |
| 96367 | <1% | 353 | $5K | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 1,666 | $5K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 460 | $5K |
| 99152 | <1% | 796 | $5K | |
| 87070 | <1% | 1,763 | $4K | |
| 73590 | <1% | 306 | $4K | |
| 82728 | <1% | 1,393 | $4K | |
| 74022 | <1% | 194 | $4K | |
| 84439 | <1% | 1,440 | $4K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 5,993 | $4K |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 6,353 | $4K |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 1,415 | $4K |
| 73080 | <1% | 231 | $4K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 36 | $4K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 12,477 | $4K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 216 | $4K |
| 93880 | <1% | 47 | $3K | |
| 58571 | <1% | 33 | $3K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,659 | $3K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 7,132 | $3K |
| 84100 | <1% | 2,207 | $3K | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 1,887 | $3K |
| 85046 | <1% | 2,039 | $3K | |
| 86644 | <1% | 489 | $3K | |
| 87205 | <1% | 2,221 | $3K | |
| 82570 | <1% | 1,057 | $3K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 4,846 | $3K |
| 84550 | <1% | 1,239 | $3K | |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | <1% | 37 | $3K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 16 | $3K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,418 | $2K |
| 87210 | <1% | 1,117 | $2K | |
| 76818 | <1% | 30 | $2K | |
| 83615 | <1% | 811 | $2K | |
| 76870 | <1% | 66 | $2K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 913 | $2K |
| 80069 | <1% | 993 | $2K | |
| 84132 | <1% | 1,547 | $2K | |
| 85652 | <1% | 1,630 | $2K | |
| 0250 | <1% | 63 | $2K | |
| 84156 | <1% | 1,007 | $2K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 94 | $2K |
| 87276 | <1% | 469 | $2K | |
| 87486 | <1% | 114 | $2K | |
| 87581 | <1% | 114 | $2K | |
| 87275 | <1% | 470 | $2K | |
| J3490 | Unclassified drugs | <1% | 133 | $2K |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 12 | $1K |
| 82330 | <1% | 267 | $1K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 14 | $1K |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 799 | $1K |
| C1781 | Mesh (implantable) | <1% | 44 | $1K |
| 86780 | <1% | 279 | $1K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 7,881 | $1K |
| C1751 | Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) | <1% | 21 | $1K |
| 12001 | <1% | 30 | $1K | |
| 73502 | <1% | 57 | $1K | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 711 | $1K |
| 74230 | <1% | 12 | $1K | |
| 29125 | <1% | 28 | $909.70 | |
| 82140 | <1% | 213 | $908.79 | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 679 | $837.70 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 132 | $825.85 |
| 87420 | <1% | 170 | $768.13 | |
| 82565 | <1% | 558 | $754.99 | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 235 | $739.54 |
| J0456 | Injection, azithromycin, 500 mg | <1% | 311 | $711.01 |
| 85660 | <1% | 732 | $683.70 | |
| 87081 | <1% | 470 | $635.97 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 417 | $626.90 |
| 82010 | <1% | 224 | $619.87 | |
| G0008 | Administration of influenza virus vaccine | <1% | 109 | $609.00 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 489 | $594.61 |
| 85018 | <1% | 869 | $580.68 | |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 141 | $564.49 |
| 85014 | <1% | 806 | $554.15 | |
| J3486 | Injection, ziprasidone mesylate, 10 mg | <1% | 15 | $533.81 |
| 88307 | <1% | 74 | $532.14 | |
| 83021 | <1% | 92 | $507.71 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 86 | $479.42 |
| 87430 | <1% | 145 | $474.33 | |
| 83550 | <1% | 250 | $464.72 | |
| 90686 | <1% | 108 | $451.08 | |
| J3105 | Injection, terbutaline sulfate, up to 1 mg | <1% | 201 | $430.77 |
| 72040 | <1% | 40 | $420.21 | |
| 92610 | <1% | 12 | $388.10 | |
| 83540 | <1% | 247 | $368.43 | |
| 84295 | <1% | 246 | $359.28 | |
| 83020 | <1% | 225 | $357.16 | |
| 88312 | <1% | 261 | $289.54 | |
| 97116 | <1% | 76 | $275.66 | |
| 82947 | <1% | 215 | $269.24 | |
| J0692 | Injection, cefepime hydrochloride, 500 mg | <1% | 84 | $258.20 |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 114 | $212.96 |
| J3360 | Injection, diazepam, up to 5 mg | <1% | 18 | $206.44 |
| 72072 | <1% | 24 | $201.18 | |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 178 | $187.66 |
| 71101 | <1% | 12 | $182.97 | |
| 94645 | <1% | 14 | $156.63 | |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | <1% | 26 | $88.65 |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 12 | $82.11 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 139 | $81.40 |
| 82248 | <1% | 33 | $78.66 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 990 | $70.63 |
| 85007 | <1% | 110 | $65.80 | |
| J1836 | Injection, metronidazole, 10 mg | <1% | 97 | $65.77 |
| 99153 | Mod sedat endo service >5yrs | <1% | 114 | $53.76 |
| 82607 | <1% | 20 | $53.47 | |
| A9270 | Non-covered item or service | <1% | 14,640 | $51.20 |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 42 | $43.92 |
| J0736 | Injection, clindamycin phosphate, 300 mg | <1% | 35 | $37.53 |
| J0461 | Injection, atropine sulfate, 0.01 mg | <1% | 67 | $17.75 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 16 | $14.96 |
| 84520 | <1% | 24 | $13.55 | |
| J1920 | Injection, labetalol hydrochloride, 5 mg | <1% | 15 | $4.97 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 179 | $4.20 |
| G8987 | Self care functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 123 | $0.00 |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 132 | $0.00 |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 191 | $0.00 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 902 | $0.00 |
| C1729 | Catheter, drainage | 0% | 218 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 303 | $0.00 |
| 0353U | 0% | 202 | $0.00 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 322 | $0.00 |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 0% | 113 | $0.00 |
| G8989 | Self care functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 52 | $0.00 |
| 97537 | 0% | 76 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialFILTON, STEVE (CFO, SENIOR VP)
| Provider | Location | Paid |
|---|---|---|
| District Hospital Partners L P | Washington, DC | $136.25M |
| Mcallen Hospitals L P | Edinburg, TX | $124.61M |
| Lancaster Hospital Corporation | Palmdale, CA | $108.63M |
| Universal Health Services of Rancho Springs INC | Murrieta, CA | $61.95M |
| Doctors Hospital of Laredo | Laredo, TX | $52.31M |
| Valley Hospital Medical Center | Las Vegas, NV | $47.03M |
| Northwest Texas Healthcare System INC | Amarillo, TX | $44.81M |
| Uhs of Bowling Green LLC | Bowling Green, KY | $41.21M |
| Uhs-Corona INC | Corona, CA | $35.18M |
| Spring Valley Medical Center | Las Vegas, NV | $33.58M |
| Aiken Regional Medical Centers LLC | Aiken, SC | $31.51M |
| Manatee Memorial Hospital L P | Bradenton, FL | $22.33M |
| Desert Springs Hospital | Las Vegas, NV | $22.29M |
| Fort Duncan Medical Center LP | Eagle Pass, TX | $15.80M |
| Psi Pride Institute INC | Eden Prairie, MN | $15.57M |
| Uhs of Fuller INC | S Attleboro, MA | $13.47M |
| Uhs of Texoma, INC | Denison, TX | $12.51M |
| Arbour INC | Boston, MA | $12.36M |
| Wellington Regional Medical Center LLC | Wellington, FL | $10.75M |
| Friends Behavioral Health System, LP | Philadelphia, PA | $9.55M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.